According to its group managing director Leonard Ariff Abdul Shatar, (pic) the group’s improved revenue was due to higher demand for Duopharma’s pharmaceutical products from the private health sector.
PETALING JAYA: Duopharma Biotech Bhd
posted a 6.2% dip in net profit for the first quarter of the financial year of 2020 (FY20) due to weaker ringgit against the US dollar.
The pharmaceutical group reported a net profit of RM13.56mil compared with RM14.47mil in the corresponding quarter a year earlier.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
